(Press-News.org) A new paper surveying advances in diabetes pathogenesis and treatment explores the complex factors contributing to the onset and progression of the disease, suggesting that an understanding of these dynamics is key to developing targeted interventions to reduce the risk of developing diabetes and managing its complications.
In a paper published July 25 in a special 50th anniversary issue of the peer-reviewed journal Cell, the authors surveyed hundreds of studies that have emerged over the years looking at the causes underpinning types 1 (T1D) and 2 (T2D) diabetes and new treatments for the disease. They examine the role that genes, environmental factors, and social determinants of health play and diabetes’ effect on cardiovascular and kidney disease.
What they found shows there are many advances in treatments that could stem the tide of a disease that has struck millions of people around the globe and continues to grow. In addition, some of these advances could be used to treat other disorders. But there are still challenges ahead.
“As the prevalence of diabetes continues to grow around the world, it is important to understand the latest advancements in research so that clinicians can provide the best care to their patients, and patients can make informed choices that support improved health outcomes,” said lead author Dr. E. Dale Abel, chair of the UCLA Department of Medicine. “This is an educational resource that integrates the latest research and trends in diabetes management, which may have implications for clinical practice as the diabetic patient population continues to grow.
“This review will be the go-to reference for physicians and researchers, providing a state-of-the-art update of where the field is currently, and where it is headed,” Abel added.
Most people are affected by type 2 diabetes, for which inadequate diet and obesity are important underlying causes. Type 1 diabetes accounts for fewer than 5% of all cases. As of 2021 about 529 million people around the world were diagnosed with diabetes, representing about 6.1% of the global population, or about one in 16 people. Prevalence in some regions is as high as 12.3%. Type 2 diabetes comprises about 96% of cases, with more than half due to obesity. Some 1.31 billion people are projected to have the disease by 2050, with prevalence rising as high as 16.8% in North Africa and the Middle East and 11.3% in Latin America and the Caribbean, the researchers write.
Genetics, the central nervous system, and the interplay between various organs as well as social and environmental factors such as food insecurity and air pollution play a role in development of diabetes.
But some recent discoveries represent significant strides toward managing and perhaps even reversing the disease. For instance, a 2019 study found that a 14-day course of the antibody teplizumab delayed the progression of type 1 diabetes from stage 1 to stage 3 by 24 months. A follow-up analysis in 2021 showed that the delay could be up to 32.5 months.
Based on these results, the U.S. Food and Drug Administration approved teplizumab as the first disease-modifying therapy for type 1 diabetes, the researchers write.
Advances in insulins with optimized pharmacokinetics, algorithm-driven subcutaneous insulin pumps, continuous glucose monitoring, and improved tools for self-management have significantly improved the quality of life and outcomes for people with stage 3 type 1 diabetes.
In addition, stem cells could replace insulin-producing cells that are lost in type 1 diabetes, Abel said.
For type 2 diabetes, three classes of glucose-lowering medicines that were introduced in the last 20 years -- GLP1RAs (glucagon like peptide-1 receptor agonists), DPP-4 inhibitors, and SGLT-2 inhibitors -- have enabled people to control their glucose levels without gaining weight and with a low risk of developing hypoglycemia. Personalized and precision medicine approaches are being explored to target the molecular mechanisms behind diabetes. However, they must demonstrate that benefits are clinically superior to standard care and are cost-effective. Also, it remains to be seen if precision approaches can be implemented in all settings worldwide, including those with few resources.
Combinations of GLP1Ras and with molecules that target other receptors such as GIP have shown even greater efficacy in treating diabetes. Recent trials have also shown that they are very effective in treating obesity, certain types of heart failure and even sleep apnea, in part because of their potency to induce weight loss and reduce inflammation. Clinical trials are now underway to test their efficacy in treating other disorders such as Alzheimer’s disease, Abel said.
“Advances in therapy now raise the hope of preventing or curing T1D and treating T2D in ways that not only improve metabolic homeostasis, but also concretely reduce the risk and progression of cardio-renal disease,” the researchers write. “Finally, as we understand and develop tools for discerning the underlying heterogeneity leading to diabetes and its complications, the stage will be set for targeting therapies and prevention strategies to optimize their impact, in ways that will be broadly applicable across diverse populations and availability of health care resources.”
Additional co-authors are Anna Gloyn of Stanford University, Carmella Evans-Molina of Indiana University, Joshua Joseph of The Ohio State University, Shivani Misra of Imperial College London, Utpal Pajvani of Columbia University, Judith Simcox of University of Wisconsin-Madison, Katalin Susztak of University of Pennsylvania, and Daniel Drucker of University of Toronto.
The research programs of study authors have been funded by the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK127236, U01DK127786, U01DK127382, R01 DK127308, R01DK133881, UC4 DK104166, P30 DK097512, UM1 DK126185, U01DK123743, U24DK098085, P30DK11607406, R01DK132403, AHRQ R01HS028822, DK103818, DK119767, R01DK133479), National Heart, Lung and Blood Institute (RO1DK125079, R61HL141783), American Heart Association (20SFRN35120123, 23SFRNCCS1052486, 23SFRNPCS1067039, 24FIM1266846), U.S. Department of Veterans Affairs Merit Award (I01BX001733), Wellcome Trust (095101, 200837), Wellcome Trust Career Development Award (223024/Z/21/Z), Glenn Foundation, American Federation for Aging Research (A22068); Hatch Grant (WIS04000-1024796); JDRF (JDRF201309442); Canadian Institutes of Health Research (154321), a BBDC-Novo Nordisk Chair in Incretin Biology, and Sinai Health-Novo Nordisk Fund in Regulatory Peptides.
END
Recent insights and advances in treatment and management show promise in stemming the growing prevalence of diabetes
2024-07-26
ELSE PRESS RELEASES FROM THIS DATE:
Folded peptides are more electrically conductive than unfolded peptides
2024-07-26
What puts the electronic pep in peptides? A folded structure, according to a new study in the Proceedings of the National Academy of Sciences.
Electron transport, the energy-generating process inside living cells that enables photosynthesis and respiration, is enhanced in peptides with a collapsed, folded structure. Interdisciplinary researchers at the Beckman Institute for Advanced Science and Technology combined single-molecule experiments, molecular dynamics simulations and quantum mechanics to validate their findings.
“This discovery provides a new understanding of how electrons flow through peptides ...
Biotechnology companies can sustain the pipeline of new drugs under the Inflation Reduction Act
2024-07-26
BENTLEY UNIVERSITY
New research from the Center for Integration of Science and Industry at Bentley University shows that differences between the financial structures of large pharmaceutical producers and smaller, emerging biotechnology companies creates synergies that contribute to the pipeline of new, innovative products in response to reductions in drug prices anticipated under the Inflation Reduction Act (IRA). While large pharmaceutical producers would likely reduce R&D spending in response to lower product revenues, R&D in smaller biotechnology companies is not likely to decrease and could sustain both corporate profits and new product ...
65 million Americans now own firearms for protection, suggests survey
2024-07-26
Some 65 million Americans now own firearms for protection—around 80% of the country’s estimated 81 million gun owners—suggest the results of a nationally representative survey carried out in 2023, and published online in the journal Injury Prevention.
This perceived need is changing the profile of gun owners, the findings indicate, with increasing numbers of women and those of minority ethnic backgrounds citing protection as the primary reason for owning a firearm.
In 2021, firearms caused the highest ...
More than 10-fold difference in rates of unintentional gun deaths across US states
2024-07-26
There’s more than a 10-fold difference in the rates of unintentional gun deaths across US states, with such incidents claiming more than 12,000 lives between 2001 and 2021, finds research published online in the journal Injury Prevention.
Poverty, rural residency, non-White ethnicity and firearms ownership are all associated with higher rates, the findings show.
Firearms kill over 130 Americans every day. Most of these deaths are intentional, but of the 48,830 firearm related deaths in 2021, 549 were unintentional, note the researchers. But it’s not clear if rates differ within and between states.
To explore this further, the researchers looked ...
Unplanned pregnancies among active service women likely curb US military readiness
2024-07-26
Unplanned pregnancies among active service women may be curbing overall US military readiness for action and compromising its Women Peace and Security objectives, suggests research published online in the journal BMJ Military Health.
That’s because they potentially result in the loss of an estimated 2.5 million to more than 4.5 million active duty days, depending on the denominator used, the findings indicate, with the highest rates among 18-24 year olds, those of White race, those deployed in junior ranks and those serving in the Army.
The researchers set out to assess the impact ...
High levels of ozone and grass pollen expected for Paris Olympics/Paralympics
2024-07-26
High levels of the respiratory irritant ozone and grass pollen are likely during the 2024 Olympic and Paralympic Games if hot, sunny weather prevails, suggests an analysis of historic air quality monitoring data for the city of Paris and surrounding area during previous summers, and published online in the British Journal of Sports Medicine.
Athletes can be affected by environmental factors, despite generally being in good physical condition, note the researchers. Breathing in air pollution during exercise may pose health risks, depending on exposure levels and underlying long term conditions, they add. Endurance athletes are particularly susceptible to allergic symptoms, they say.
To ...
CDA creates new industry partner program
2024-07-26
The University of Illinois Center for Digital Agriculture (CDA) has launched a new partnership program for industry members to strengthen their ties to academia, technology, multidisciplinary research and professional development in a joint effort to tackle the globe’s most pressing agricultural challenges.
Unveiled in June, the CDA Industry Partner Program (IPP) offers members the opportunity to collaborate with world-renowned researchers and field experts to solve complex problems facing the industry, whether they stem from a changing climate, personnel shortages or any other hurdles that spring up. IPP ...
Tulane study says new drug shows promise in clearing HIV from brain
2024-07-26
An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new Tulane University study.
For the first time, researchers at Tulane National Primate Research Center found that a cancer drug significantly reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain by targeting and depleting certain immune cells that harbor the virus.
Published in the journal Brain, this discovery marks a significant step toward eliminating HIV from hard-to-reach reservoirs where the virus evades otherwise effective treatment.
“This research is an important step ...
Medicaid policies increase diverse participation in cancer clinical trials
2024-07-25
Two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients, according to a new study by investigators at Weill Cornell Medicine, the University of Pennsylvania, and Medidata AI. Black and Hispanic patients are historically underrepresented in cancer clinical trials; equitable enrollment helps ensure the knowledge gained from trials generalizes to the entire population and promotes equitable patient access to the latest treatment options.
The study, published July 25 in the Journal of Clinical Oncology, examined the effect of the interaction between two Medicaid policies on the rates of enrollment for Black ...
Study identifies unique treatment preference profiles in men with prostate cancer
2024-07-25
A team of investigators from UCLA has identified distinct patient preference-based profiles among men diagnosed with low-risk prostate cancer regarding their treatment options that could help enhance shared decision-making and patient satisfaction in prostate cancer care.
The study, published in Urology Practice, reveals that while there were clear differences in treatment preferences among the profiles, these preference profiles did not significantly influence the patients' final treatment choices.
“Men ...